Dr Luc-André Granier
M.D., PhD: CEO and Medical Director
Luc-André Granier founded Advicenne and has been Medical Director and Chairman of the Board since 2011. Luc-André Granier is an expert in the pharmaceutical development of innovative therapeutic products in the field of the central nervous system (CNS) with more than 25 years’ experience in the pharmaceutical (Eli Lilly and Co) and biotechnology (Synt:em, Forenap) industries. He has conducted a large number of clinical trials and led numerous programs for the development of drugs to treat neurological disorders, mainly in the fields of pain, migraine, neuro-degenerative diseases and psychiatric disorders. In particular, he successfully conducted the proof of concept study for the “blockbuster” duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004. Dr Granier obtained his degree as a Doctor of Medicine and Doctor of Science (in Biochemistry and Molecular and Cellular Biology) at the Louis Pasteur University in Strasbourg, France. He is a member of several national and international scientific societies, in particular in the fields of pain (SFETD, IHS, IASP) and epilepsy (ILAE).
Mrs. Caroline Roussel-Maupetit
Director of Operations, General Manager
Caroline Roussel-Maupetit is the co-founder and General Manager of Advicenne. She is responsible for pharmaceutical development and project management for the company. Caroline Roussel-Maupetit has an engineering degree in Industrial Biology from the UTC (France) and is a management school graduate (IEDE Montpellier). She has extensive experience in research project management and in sub-contracting early clinical projects. In 1995, Ms. Roussel was the co-founder of Synt:em, a French biotech company with intensive preclinical and clinical activities, where she held the position of Chief Operations Officer. She was mainly responsible for the pharmaceutical development of drug candidates in preclinical and clinical development in the field of acute pain, neuropathic pain and oncology.
Financial & Logistics Director
Sarah Delbaere joined Advicenne in November 2013 as Financial & Logistics Director; her experience of more than 15 years in the pharmaceutical & biotechnology sector will contribute to the companies’ development. She worked for several international companies in France en and Belgium, and is familiar with the commercial departments of big pharma, but also with research & development activities of start-ups. Graduated in applied economics at the University of Antwerp in Belgium, she started her career as financial controller at Innogenetics, a biotechnology company listed on NASDAQ and moved to France to join Gencell, an affiliate of Sanofi-Aventis, specialized in gene therapy. As Financial and Administrative director of Nycomed France, merged with Takeda in 2011, she was responsible for finance, supply chain, legal and general administration. She was highly involved in two mergers, and the strategic reorganization of the company.
Mrs. Catherine Guittet
Director of Clinical Research and Regulatory Affairs
Catherine Guittet, PharmD, PhD joined ADVICENNE in 2008. She is responsible for clinical research, regulatory affairs and project management. She is more especially involved in conducting Advicenne clinical trials. C Guittet has over 12 years experience in clinical and regulatory affairs. Prior to joining Advicenne, she began her career at Theraplix (Sanofi-Aventis) as Head of Project Management where she created the department. She was then responsible for early-phase and multicentre clinical trials at a top-level CRO : Aster-Cephac (SGS). She then joined Synt:em Graftys, French biotech companies, as Head of the Clinical Department. Finally, she went to Merck-Serono , where she managed a unit dedicated to the coordination of early clinical development in oncology . She has a Pharm D PhD from Angers University, graduated as Clinical Investigator from Paris VII, obtained a Pharmaco-Epidemiology Certificate from Bordeaux II University, and a Cellular Pharmacology, Pharmacogenetics and Pharmacokinetics Certificate from Paris VII University.
Mrs. Nathalie Lemarié
Chief Pharmacist & Director of Regulatory Affairs
Mrs. Nathalie Lemarié joined the Advicenne team in October 2012. She has over 20 years’ experience in Regulatory Affairs, both in France and abroad. This experience was acquired at Laboratoire Chauvin, France, where she coordinated regulatory affairs in the European subsidiaries of the group and the setting up of European registration procedures. She has therefore placed her expertise in the regulatory environment for drugs at the disposal of Advicenne, particularly for the setting up of its pharmaceutical distribution company and the registration of the pharmaceuticals developed. Her senior experience enables her to manage Regulatory Affairs and the company’s pharmaceutical sector. Mrs. Nathalie Lemarié obtained her PhD in Pharmacy and Masters in Company Administration at the University of Montpellier, France.
Mrs. Catherine Martre
Head of Strategy and Commercial Development
Graduated from the Ecole Centrale and holder of a DEA (Diplôme des Etudes Approfondies equivalent to Master of Advanced Studies) in applied chemistry and process engineering, Catherine Martre started her career as a consultant within Alcimed, dedicated to strategy consulting for health and biotechnology companies. She then joined the pharmaceutical industry in 2001. She worked for Laboratoires Altana and then Nycomed where she was responsible for market research, data management, business development and commercial effectiveness. Prior to joining Advicenne she held the position of Director of Strategy and Public Affairs at Laboratoire Takeda France, in charge of strategy, business development and public affairs, including the negotiation with French Health authorities for pricing and reimbursement of new drugs. Within Advicenne, Catherine Martre will be responsible for business development, economic affairs (pricing and reimbursement) and the marketing strategy for products of Advicenne’s portfolio, whether developed internally or as a result of partnerships. [/exergue]